ALK Gene Rearrangements: Testing, Targeted Therapy and What They Mean

ALK is a gene that normally provides instructions for a receptor tyrosine kinase, a type of protein that transmits growth signals into cells. In healthy adult tissue, ALK is largely switched off. Cancer arises when a piece of chromosome breaks and rejoins incorrectly, fusing part of the ALK gene to part of another gene. This is called a gene rearrangement, translocation or fusion.

In non-small cell lung cancer, the most common fusion partner is EML4, producing the EML4-ALK fusion gene, though dozens of other partner genes have been described. The fusion protein that results behaves like a switch stuck in the 'on' position, continuously telling the cell to grow and divide without the normal controls. This is a somatic change — it happens inside the tumour during a person's lifetime — and is not something that can be inherited or passed on to children.

ALK rearrangements are not unique to lung cancer. In anaplastic large cell lymphoma and inflammatory myofibroblastic tumour, ALK fuses with different partner genes such as NPM1. In neuroblastoma, a childhood cancer of the nervous system, ALK is altered through point mutations or amplification more often than through fusion, but the effect is similar: a growth pathway locked in the active state. Because the mechanism is shared, testing for and treating ALK-driven cancers has become a model example of biomarker-directed, or precision, oncology — the broader concept explained in our overview of what are cancer biomarkers.

If your tumour tests positive for an ALK rearrangement, the practical implication is that an oral ALK inhibitor, rather than chemotherapy, is likely to be recommended as your first treatment, and often produces a strong and durable response with a manageable side-effect profile. Because several ALK inhibitors exist, your oncologist will consider factors such as whether there is disease in the brain, your other health conditions, and the drug's side-effect and dosing profile when choosing which one to start with.

Because resistance to any single ALK inhibitor can eventually develop, your care team may plan to repeat imaging regularly and to consider re-biopsy or a blood-based liquid biopsy if the cancer begins to grow again. Finding a specific resistance mutation at that point can directly guide the choice of the next drug, rather than defaulting to chemotherapy. It is entirely reasonable to ask your oncologist which ALK inhibitor generation you are being offered, why, and what the plan would be if resistance develops — these are core elements of shared decision-making in ALK-positive disease and are also central themes in modern targeted therapy generally.

ALK-positive cancer is not diagnosed by symptoms alone; it is a molecular subtype identified through laboratory testing performed after a cancer diagnosis has already been established by biopsy and pathology review. In lung cancer, a diagnosis typically begins with imaging that reveals a mass or nodule, followed by a biopsy to confirm cancer and determine its type — most often adenocarcinoma when ALK fusions are involved. The tissue sample is then sent for biomarker testing, including ALK, as part of the standard work-up before a treatment plan is finalised.

In anaplastic large cell lymphoma, inflammatory myofibroblastic tumour and neuroblastoma, ALK status is similarly determined by testing tumour tissue obtained through biopsy or surgical resection, using IHC, FISH or sequencing depending on the suspected fusion partner and local laboratory protocols. A pathology report will state whether ALK rearrangement, mutation or amplification was detected, and this result becomes a permanent part of the medical record used to guide both initial and future treatment decisions.

ALK testing should be performed at diagnosis of advanced or metastatic non-small cell lung cancer, and is recommended by major oncology bodies as a routine part of the biomarker panel alongside EGFR, ROS1, KRAS, and PD-L1. Testing is usually done on tissue obtained from a biopsy or surgical sample, though a blood-based liquid biopsy can be used when tissue is unavailable or insufficient.

Immunohistochemistry (IHC) uses an antibody that binds specifically to the ALK protein and is a fast, widely available, highly sensitive method often used as the initial screening test; a strongly positive IHC result can, in many laboratories, be considered sufficient on its own to start ALK-targeted treatment. Fluorescence in situ hybridisation (FISH) uses fluorescent probes to visualise the physical rearrangement of the ALK gene under a microscope and has long been considered a reference-standard confirmatory test, particularly for equivocal IHC results. Next-generation sequencing (NGS) panels, run on DNA or RNA, can detect ALK fusions alongside dozens of other genes in a single test, identify the specific fusion partner, and — importantly at the point of disease progression — detect the specific resistance mutations that have emerged, information that IHC and FISH cannot provide.

Because different fusion partners and breakpoints exist, RNA-based NGS is considered particularly sensitive for detecting unusual or novel ALK fusions that DNA-based panels might miss. Turnaround time for a full panel is typically one to two weeks; results are combined with testing for other lung cancer biomarkers so that treatment can be personalised as fully as possible before therapy starts.

ALK alterations are best characterised in non-small cell lung cancer, where the EML4-ALK fusion accounts for the large majority of ALK-positive cases, though other rarer fusion partners exist. This subgroup tends to occur in relatively younger patients, is strongly associated with adenocarcinoma histology, and is more frequent among people who have never smoked or smoked lightly, though it is not exclusive to this group.

Anaplastic large cell lymphoma (ALCL), a type of T-cell non-Hodgkin lymphoma, is frequently ALK-positive, especially in children and younger adults, typically through an NPM1-ALK fusion; ALK-positive ALCL generally has a more favourable prognosis than ALK-negative disease. Inflammatory myofibroblastic tumour, an uncommon soft-tissue tumour that can occur in children and adults, carries ALK rearrangements in roughly half of cases and can respond well to ALK-targeted therapy, an important alternative to more extensive surgery in some patients. Neuroblastoma, one of the more common solid tumours of early childhood, can carry ALK activating point mutations or gene amplification, most often in high-risk or familial cases, and ALK status is now assessed as part of risk stratification in specialised paediatric oncology centres.

For ALK-positive advanced non-small cell lung cancer, first-line treatment is typically an oral ALK inhibitor selected in part for its ability to control disease in the brain and its expected durability against emerging resistance. If the cancer progresses, options depend on whether a resistance mutation is identified: a different ALK inhibitor active against that specific mutation may be used, or treatment may move to chemotherapy, sometimes combined with immunotherapy, if no further ALK-directed option is suitable. Enrolment in a clinical trial of a newer ALK inhibitor or combination strategy is a reasonable option at any point, particularly after resistance to multiple prior ALK inhibitors. For ALCL, inflammatory myofibroblastic tumour and neuroblastoma, treatment plans are individualised in specialised centres and may combine ALK inhibitors with chemotherapy, radiotherapy or surgery depending on the extent of disease.